You are here:

albiglutide (Eperzan)

Advice

following a full submission

albiglutide (Eperzan®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

SMC restriction: an alternative once weekly glucagon-like peptide-1 (GLP-1) agonist for use in combination with oral anti-diabetic agents as a third-line pre-insulin treatment option.

As add-on combination therapy, albiglutide was superior to placebo and to some oral comparators for glycaemic control.  It was inferior to an alternative GLP-1 agonist and non-inferior to insulin. 

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of albiglutide. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Albiglutide is also indicated for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy when diet and exercise alone does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.  SMC has not reviewed albiglutide in this indication and cannot recommend its use within NHS Scotland.

Drug Details

Drug Name: albiglutide (Eperzan)
SMC Drug ID: 1024/15
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 January 2016

Extra Notes

GSK will discontinue the commercial sale and availability of albiglutide (Eperzan) worldwide. Commercial supplies will no longer be available in the UK from July 2018.

Back